In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST / F. Raffi, M. Battegay, S. Rusconi, M. Opravil, G. Blick, R. T. Steigbigel, M. Kraft, D. Neubacher, J. P. Sabo. - In: AIDS. - ISSN 0269-9370. - 21:14(2007 Sep 12), pp. 1977-80-1980.
|Titolo:||Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST|
|Parole Chiave:||Randomized Controlled Trials as Topic; HIV Protease Inhibitors; Liver Diseases; Pyrones; Anti-HIV Agents; Saquinavir; Humans; Pyridines; HIV-1; Alanine Transaminase; Viral Load; Drug Therapy, Combination; HIV Envelope Protein gp41; Drug-Induced Liver Injury; Peptide Fragments; Lopinavir; Ritonavir; HIV Infections; Pyrimidinones; Treatment Outcome; HIV Fusion Inhibitors|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||12-set-2007|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1097/QAD.0b013e3282ef8600|
|Appare nelle tipologie:||01 - Articolo su periodico|